Travere Therapeutics (RTRX) Stock Price, News & Analysis

Company Overview

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Key Stats

• Today's Range: $14.37 to $14.93
• 50-Day Range: $24.25 to $28.18
• 52-Week Range: $8.98 to $24.96
• Volume: 1.58 million shs
• Average Volume: 412,277 shs
• Market Capitalization: $740.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RTRX Stock Analysis - Frequently Asked Questions

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:RTRX) released its earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.15. Travere Therapeutics had a negative net margin of 49.13% and a negative trailing twelve-month return on equity of 36.38%.

What other stocks do shareholders of Travere Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Travere Therapeutics investors own include CVS Health (CVS), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Novavax (NVAX), TG Therapeutics (TGTX), Dynavax Technologies (DVAX) and Intercept Pharmaceuticals (ICPT).

Company Calendar

• Last Earnings: 11/05/2020
• Today: 6/14/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:RTRX
• CIK: 1438533
• Web: www.retrophin.com
• Phone: (888) 969-7879
• Fax: N/A
• Employees: 221
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$146.43 million
• Net Margins: -49.13%
• Pretax Margin: N/A
• Return on Equity: -36.38%
• Return on Assets: -14.90%

Debt

• Debt-to-Equity Ratio: 0.66
• Current Ratio: 7.23
• Quick Ratio: 7.14

Sales & Book Value

• Annual Sales: $175.34 million
• Price / Sales: 4.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.15 per share
• Price / Book: 2.82

Miscellaneous

• Outstanding Shares: 51,052,000
• Free Float: N/A
• Market Cap: $740.25 million
• Optionable: Not Optionable
• Beta: 0.67